Bluepharma invests EUR 200m in factory expansion in Coimbra, planning to enter vaccine market over the next five years
|
27 JUN 2021
|
Intel ID : 326967
|
||||
| Intel ID | 326967 | ||
| Value | EUR 200,00m | ||
| Native Currency | Euro (EUR) | ||
|
Financial Data - Bluepharma Genéricos
(31 Dec 2022) |
Revenue: EUR 11,48m EBITDA: EUR 0,86m Net Debt: EUR 5,56m People: 19 |
||
| Date |
 |
||
| Country |  |
||
| Geography | |
||
| Subsector (Old TTR Sectors) |
|
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | |
||
| Jobs Created |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.